Analysis of paired biopsies showed increased tumor infiltration of CD25+ activated CD8+ T cells and NK cells post-MDNA11 treatment. Combination Dose ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 ...

"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...

Most were what one might expect from cancer immunotherapies – skin and subcutaneous ... which first established Keytruda monotherapy as the standard of care for PFD-L1-high NSCLC, showed a ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

BCC is new territory for cancer immunotherapies however, and Libtayo is the first drug in the PD-1/PD-L1 inhibitor class to get go-ahead in this common form of skin cancer.

Wellness enthusiasts have a new reason to celebrate as MD Logic Health® introduces Chocolate Collagen, a bovine collagen supplement that delivers the best of both worlds: great taste and wellness ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...